신경통 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Neuralgia Treatment Market Size, Share & Trends Analysis Report By Treatment (Drug Based, Surgery), By End Use (Hospital & Clinics, Ambulatory Surgery Centers), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

신경통 치료 시장 성장과 동향

세계 신경통 치료 시장 규모는 2030년 34억 3,000만 달러에 달할 것으로 예상되며, 2025-2030년까지 연평균 6.7%의 성장률을 기록할 것으로 전망됩니다. 노인 인구 증가, 삼차 신경통 발생률 증가, 당뇨병 유병률 증가가 시장을 이끄는 주요 요인입니다. 신경통은 신경의 손상이나 염증으로 인한 작열감, 찌르는 듯한 극심한 통증을 말합니다.

신경의 만성 통증은 감염, 당뇨병, 노화, 다발성 경화증, 또는 특정 신경을 보호하는 수초를 손상시키는 유사한 질환 등 다양한 요인으로 인해 발생할 수 있습니다. 삼차 신경을 압박하는 종양도 이 질환의 원인이 될 수 있습니다. 삼차신경 만성 통증의 유병률은 고령화와 함께 증가하는데, WHO의 추정에 따르면 2015년 9억 명에서 2050년 20억 명으로 증가할 것으로 예상됩니다. 노인들은 당뇨병, 삼차신경통 등 많은 질병에 걸리기 쉽습니다.

미국 신경근 및 전기진단의학협회에 따르면 삼차신경통은 보통 50세 이상에서 발병합니다. 또한 삼차신경통은 남성보다 여성에게 더 많이 발생하며, International Association for The Study of Pain(IASP)에서 발표한 The Patient's Journey Through Trigeminal Neuralgia라는 연구에 따르면, 일반 인구의 삼차신경통 발병률은 인구 10만 명당 3.4-5.9명입니다. 또한, 노년층의 발병률이 상대적으로 높은 것으로 보고되고 있습니다. 이러한 요인들은 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 정위적 방사선 수술과 미세혈관 감압술은 이 질환을 치료하기 위해 가장 일반적으로 사용되는 치료법입니다.

신경통 치료 시장 보고서 하이라이트

• 외과 수술 부문은 2024년 64.8%의 점유율을 차지하며 시장을 장악했습니다. 로봇을 이용한 방사선 수술과 같은 정확하고 비침습적인 치료 옵션에 대한 수요 증가가 이 부문의 주요 촉진요인으로 작용하고 있습니다.
• 제약 기반 부문은 예측 기간 동안 가장 빠른 CAGR 7.0%로 성장할 것으로 예상됩니다.
• 병원 및 클리닉 부문은 2024년 가장 큰 시장 수익 점유율을 차지했습니다. 병원 및 클리닉의 첨단 비침습적 기술 채택은 보다 정확하고 표적화된 치료를 제공함으로써 시장을 주도할 것으로 예상됩니다.
• 외래 수술 센터 부문은 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 신경통 치료 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 신경통 치료 시장 : 치료별 비즈니스 분석

• 치료 시장 점유율, 2024년과 2030년
• 치료 부문 대시보드
• 시장 규모와 예측과 동향 분석, 치료별, 2018-2030년
• 약제 기반
• 수술

제5장 신경통 치료 시장 : 최종 용도별 비즈니스 분석

• 최종 용도 시장 점유율, 2024년과 2030년
• 최종 용도 부문 대시보드
• 시장 규모와 예측과 동향 분석, 최종 용도별, 2018-2030년
• 병원·클리닉
• 외래 수술 센터
• 기타

제6장 신경통 치료 시장 : 국가별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 러시아
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 참여자 개요
• 기업의 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 개요/상장 기업
  • GSK plc.
  • Pfizer Inc.
  • Novartis AG
  • Biogen
  • Zydus Group(Cadila Healthcare Limited)
  • H. Lundbeck A/S

ksm

영문 목차

영문목차

Neuralgia Treatment Market Growth & Trends:

The global neuralgia treatment market size is expected to reach USD 3.43 billion in 2030 and is projected to grow at a CAGR of 6.7% from 2025 to 2030. The rising geriatric population, increasing incidence of trigeminal neuralgia, and the growing prevalence of diabetes are the key factors driving the market. Neuralgia is a burning, stabbing, and severe pain due to a damaged or irritated nerve.

The chronic pain in the nerves can occur due to various factors such as infection, diabetes, aging, multiple sclerosis, or any similar disorders that damage the myelin sheath protecting certain nerves. Tumor compressing the trigeminal nerve can also cause the disorder. The prevalence of chronic pain in the trigeminal nerve increases with the aging population. According to the estimates published by the WHO, the geriatric population is anticipated to rise from 900.0 million in 2015 to 2.0 billion in 2050. The geriatric population is prone to many diseases such as diabetes and trigeminal neuralgia.

As per the American Association of Neuromuscular and Electrodiagnostic Medicine, the disorder usually affects the population aged 50 years or older. It also reported that women are more prone to trigeminal neuralgia than men. As per the study, The Patient's Journey Through Trigeminal Neuralgia published by the International Association for The Study of Pain (IASP), the incidence rate of the disorder in the general population is 3.4 to 5.9 per 100,000 population. It also reported that the incidence rate is comparatively higher in the geriatric population. Such factors are expected to boost market growth over the forecast period. Stereotactic radiosurgery and microvascular decompression are the two most common procedures being adopted to treat the disorder.

Neuralgia Treatment Market Report Highlights:

• The surgery segment dominated the market and accounted for a share of 64.8% in 2024. The growing demand for precise, non-invasive treatment options, such as robotic radiosurgery, is a key driver for the segment
• The drug-based segment is expected to grow at the fastest CAGR of 7.0% over the forecast period
• The hospital & clinics segment accounted for the largest market revenue share in 2024. Adopting advanced, non-invasive technologies in hospitals and clinics drives the market by providing more accurate and targeted treatments
• The ambulatory surgery centers segment is expected to grow at the fastest CAGR over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Neuralgia Treatment Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Neuralgia Treatment Market: Treatment Business Analysis

• 4.1. Treatment Market Share, 2024 & 2030
• 4.2. Treatment Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
• 4.4. Drug Based
  • 4.4.1. Drug based market, 2018 - 2030 (USD Million)
  • 4.4.2. Anticonvulsant medicines
    • 4.4.2.1. Anticonvulsant medicines market, 2018 - 2030 (USD Million)
  • 4.4.3. Tricyclic antidepressants
    • 4.4.3.1. Tricyclic antidepressants market, 2018 - 2030 (USD Million)
• 4.5. Surgery
  • 4.5.1. Surgery market, 2018 - 2030 (USD Million)
  • 4.5.2. Radiofrequency Thermal Lesioning
    • 4.5.2.1. Radiofrequency thermal lesioning market, 2018 - 2030 (USD Million)
  • 4.5.3. Stereotactic Radiosurgery
    • 4.5.3.1. Stereotactic radiosurgery market, 2018 - 2030 (USD Million)
  • 4.5.4. Microvascular Decompression
    • 4.5.4.1. Microvascular decompression market, 2018 - 2030 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Neuralgia Treatment Market: End Use Business Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 5.4. Hospital & Clinics
  • 5.4.1. Hospital & clinics market, 2018 - 2030 (USD Million)
• 5.5. Ambulatory Surgery Centers
  • 5.5.1. Ambulatory surgery centers market, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others market, 2018 - 2030 (USD Million)

Chapter 6. Neuralgia Treatment Market: Country Estimates & Trend Analysis by Product and Technology

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key country dynamic
    • 6.4.2.2. Regulatory framework
    • 6.4.2.3. Competitive insights
    • 6.4.2.4. U.S. neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key country dynamic
    • 6.4.3.2. Regulatory framework
    • 6.4.3.3. Competitive insights
    • 6.4.3.4. Canada neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key country dynamic
    • 6.4.4.2. Regulatory framework
    • 6.4.4.3. Competitive insights
    • 6.4.4.4. Mexico neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key country dynamic
    • 6.5.2.2. Regulatory framework
    • 6.5.2.3. Competitive insights
    • 6.5.2.4. UK neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key country dynamic
    • 6.5.3.2. Regulatory framework
    • 6.5.3.3. Competitive insights
    • 6.5.3.4. Germany neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key country dynamic
    • 6.5.4.2. Regulatory framework
    • 6.5.4.3. Competitive insights
    • 6.5.4.4. France neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key country dynamic
    • 6.5.5.2. Regulatory framework
    • 6.5.5.3. Competitive insights
    • 6.5.5.4. Italy neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key country dynamic
    • 6.5.6.2. Regulatory framework
    • 6.5.6.3. Competitive insights
    • 6.5.6.4. Spain neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Russia
    • 6.5.7.1. Key country dynamic
    • 6.5.7.2. Regulatory framework
    • 6.5.7.3. Competitive insights
    • 6.5.7.4. Russia neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key country dynamic
    • 6.5.8.2. Regulatory framework
    • 6.5.8.3. Competitive insights
    • 6.5.8.4. Denmark neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Sweden
    • 6.5.9.1. Key country dynamic
    • 6.5.9.2. Regulatory framework
    • 6.5.9.3. Competitive insights
    • 6.5.9.4. Sweden neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.10. Norway
    • 6.5.10.1. Key country dynamic
    • 6.5.10.2. Regulatory framework
    • 6.5.10.3. Competitive insights
    • 6.5.10.4. Norway neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key country dynamic
    • 6.6.2.2. Regulatory framework
    • 6.6.2.3. Competitive insights
    • 6.6.2.4. Japan neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key country dynamic
    • 6.6.3.2. Regulatory framework
    • 6.6.3.3. Competitive insights
    • 6.6.3.4. China neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key country dynamic
    • 6.6.4.2. Regulatory framework
    • 6.6.4.3. Competitive insights
    • 6.6.4.4. India neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key country dynamic
    • 6.6.5.2. Regulatory framework
    • 6.6.5.3. Competitive insights
    • 6.6.5.4. Australia neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Thailand
    • 6.6.6.1. Key country dynamic
    • 6.6.6.2. Regulatory framework
    • 6.6.6.3. Competitive insights
    • 6.6.6.4. Thailand neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. South Korea
    • 6.6.7.1. Key country dynamic
    • 6.6.7.2. Regulatory framework
    • 6.6.7.3. Competitive insights
    • 6.6.7.4. South Korea neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key country dynamic
    • 6.7.2.2. Regulatory framework
    • 6.7.2.3. Competitive insights
    • 6.7.2.4. Brazil neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key country dynamic
    • 6.7.3.2. Regulatory framework
    • 6.7.3.3. Competitive insights
    • 6.7.3.4. Argentina neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key country dynamic
    • 6.8.2.2. Regulatory framework
    • 6.8.2.3. Competitive insights
    • 6.8.2.4. South Africa neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key country dynamic
    • 6.8.3.2. Regulatory framework
    • 6.8.3.3. Competitive insights
    • 6.8.3.4. Saudi Arabia neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key country dynamic
    • 6.8.4.2. Regulatory framework
    • 6.8.4.3. Competitive insights
    • 6.8.4.4. UAE neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key country dynamic
    • 6.8.5.2. Regulatory framework
    • 6.8.5.3. Competitive insights
    • 6.8.5.4. Kuwait neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. GSK plc.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial performance
    • 7.5.1.3. Product benchmarking
    • 7.5.1.4. Strategic initiatives
  • 7.5.2. Pfizer Inc.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial performance
    • 7.5.2.3. Product benchmarking
    • 7.5.2.4. Strategic initiatives
  • 7.5.3. Novartis AG
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial performance
    • 7.5.3.3. Product benchmarking
    • 7.5.3.4. Strategic initiatives
  • 7.5.4. Biogen
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial performance
    • 7.5.4.3. Product benchmarking
    • 7.5.4.4. Strategic initiatives
  • 7.5.5. Zydus Group (Cadila Healthcare Limited)
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial performance
    • 7.5.5.3. Product benchmarking
    • 7.5.5.4. Strategic initiatives
  • 7.5.6. H. Lundbeck A/S
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial performance
    • 7.5.6.3. Product benchmarking
    • 7.5.6.4. Strategic initiatives

관련자료